Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis

Background and Aim Thrombocytopenia (TCP) of chronic hepatitis C patients with cirrhosis has a negative impact on the management of interferon‐based treatment. The aim of this study is to evaluate the efficacy and safety of telaprevir‐based triple therapy for patients who have undergone splenectomy...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2014-09, Vol.29 (9), p.1728-1735
Main Authors: Ogawa, Eiichi, Furusyo, Norihiro, Nakamuta, Makoto, Kajiwara, Eiji, Nomura, Hideyuki, Dohmen, Kazufumi, Takahashi, Kazuhiro, Satoh, Takeaki, Azuma, Koichi, Kawano, Akira, Tanabe, Yuichi, Kotoh, Kazuhiro, Shimoda, Shinji, Akahoshi, Tomohiko, Maehara, Yoshihiko, Hayashi, Jun
Format: Article
Language:English
Subjects:
Adult
Aged
Alleles
Antiviral Agents - administration & dosage
cirrhosis
Drug Therapy, Combination
Female
hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - therapy
Humans
Interferon alpha-2
Interferon-alpha - administration & dosage
Interferons
Interleukins - genetics
Liver Cirrhosis - complications
Liver Cirrhosis - therapy
Male
Middle Aged
Oligopeptides - administration & dosage
Platelet Count
Polyethylene Glycols - administration & dosage
Prospective Studies
Recombinant Proteins - administration & dosage
Ribavirin - administration & dosage
Severity of Illness Index
Splenectomy
telaprevir
thrombocytopenia
Thrombocytopenia - blood
Thrombocytopenia - etiology
Thrombocytopenia - therapy
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Thrombocytopenia (TCP) of chronic hepatitis C patients with cirrhosis has a negative impact on the management of interferon‐based treatment. The aim of this study is to evaluate the efficacy and safety of telaprevir‐based triple therapy for patients who have undergone splenectomy (Spx). Methods This prospective, multicenter study consisted of 80 patients, including 32 Spx and 48 non‐Spx/TCP (platelet count: 60–99 × 109/L) patients with advanced fibrosis infected with hepatitis C virus genotype 1b. All received 12 weeks of telaprevir in combination with 24 weeks of pegylated interferon (PEG‐IFN) α2b and ribavirin. Results The sustained virological response (SVR) rate of the Spx group (75.0%) was significantly higher than that of the non‐Spx/TCP group (52.1%) (P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.12619